HLA-DR Antigen and Bax Protein Expression in Patients with Primary Non-Hodgkin's Gastric Lymphoma
| Autor: | A. Darom, C. Fotiadis, E. Xatziyiannis, Ilias P. Gomatos, Emmanuel Leandros, Manoussos M. Konstadoulakis |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Lymphoma B-Cell Immunology Antigen Stomach Neoplasms hemic and lymphatic diseases Biomarkers Tumor Genetics medicine Humans In patient Survival rate HLA-DR Antigen Aged bcl-2-Associated X Protein Univariate analysis business.industry Lymphoma Non-Hodgkin Gastric lymphoma HLA-DR Antigens Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease Staining Proto-Oncogene Proteins c-bcl-2 Female business BAX Protein |
| Zdroj: | Hybridoma and Hybridomics. 23:87-92 |
| ISSN: | 1536-8599 |
| DOI: | 10.1089/hyb.2004.23.87 |
| Popis: | Primary gastric lymphoma represents a rare gastrointestinal malignancy with an unclear prognosis. The aim of this study was to determine the prognostic significance of HLA-DR antigen and bax expression in patients with primary non-Hodgkin's gastric lymphoma. We immunohistochemically studied bax protein and HLA-DR antigen expression in 36 B-cell, MALT-type primary gastric lymphoma patients diagnosed and treated in our department from 1990 to 1995. Ten non-malignant gastric tissue specimens were used as benign controls. Clinicopathological and survival data were correlated with the staining results. HLA-DR antigen expression was observed in 33 gastric lymphoma patients (91.7%). Positive bax staining was found in 24 gastric lymphomas (66.7%) and in none of the benign cases studied. In the univariate analysis, those gastric lymphoma patients who expressed HLA-DR antigen in more than 15% of their tumor cells, presented a significantly improved 5-year survival rate (75% vs. 37.5%, p = 0.04). Furthermore, gastric lymphoma patients who were bax(+)/HLA-DR(+) had a statistically better overall survival compared to those who were bax(-)/HLA-DR(-) (82.4% vs. 25%, p = 0.01). HLA-DR antigen expression was associated with a favorable clinical outcome. Its expression improved the predictive value of bax protein expression in non-Hodgkin's gastric lymphoma patients. The combined use of these markers permits the identification of a high-risk group of patients that may benefit from a more aggressive therapeutic approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|